Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01518972 · ClinicalTrials.gov registry record · Phase 2
Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder
A Phase 2 study, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01518972 is a Phase 2 study that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 30 participants.
The verdict
NCT01518972, a Phase 2 study, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the drug prazosin is effective for the treatment of alcohol dependency and symptoms of Posttraumatic Stress Disorder (PTSD).
Interventions
- DRUG Prazosin
- DRUG Placebo medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-09 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01518972
The ClinicalTrials.gov registry entry for NCT01518972 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Institute for Biomedical and Clinical Research, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prazosin is the first listed.
NCT01518972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01518972 about?
NCT01518972 is a clinical study titled "Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder". The purpose of this study is to determine whether the drug prazosin is effective for the treatment of alcohol dependency and symptoms of Posttraumatic Stress Disorder (PTSD).
What is the current status of trial NCT01518972?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2009-09. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01518972?
The interventions under investigation include: Prazosin (DRUG), Placebo medication (DRUG).
Who is sponsoring clinical trial NCT01518972?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.